CLSI M07
Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically
CLSI M07 provides essential guidance for antimicrobial susceptibility testing of aerobic bacteria using broth macrodilution, broth microdilution, and agar dilution methods. This standard is crucial for determining the susceptibility of organisms involved in infectious processes when resistance patterns cannot be reliably predicted based on species identity.
Designed for laboratories performing susceptibility testing, M07 ensures accurate and standardized minimal inhibitory concentration (MIC) determinations. Every purchase includes the M07-Ed12 Quick Guide for streamlined reference. Discounted package pricing is available when purchasing the latest editions of CLSI M02, M07, and M100 together.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceClinical and Laboratory Standards Institute M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically offers guidance for antimicrobial susceptibility testing that is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism’s identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents. Various laboratory methods can be used to measure the in vitro susceptibility of bacteria to antimicrobial agents. Clinical and Laboratory Standards Institute M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically describes standard broth dilution (macrodilution and microdilution [the microdilution method described in CLSI M07 is the same methodology outlined in ISO 20776-1])1 and agar dilution techniques, and it includes a series of procedures to standardize the way the tests are performed. The performance, applications, and limitations of the current CLSI-recommended methods are also described. The supplemental information (CLSI M1002 tables) used with this standard represents the most current information for drug selection, interpretation, and QC using the procedures standardized in CLSI M07.
This standard replaces CLSI M07-Ed11, published in 2018, with several updates. General changes include revised information for testing and reporting, updated nomenclature from “coagulase-negative staphylococci” (CoNS) to “staphylococci other than Staphylococcus aureus” (SOSA), and changes in terminology from “groups” to “tiers” and “microdilution trays” to “microdilution panels.” Definitions and abbreviations have been updated, with new definitions added and some deleted. Subchapters on selecting antimicrobial agents, equivalent agents, and suggested guidelines for testing and reporting have been clarified and updated, including the addition of new tables for antimicrobial agent tiers and designations. New information on preparing and storing diluted antimicrobial agents, inoculum preparation, and inoculation methods has been included, along with updates to agar dilution procedures and special considerations for fastidious organisms and resistance detection.
Additional changes include the addition of iron-depleted cation-adjusted Mueller-Hinton broth for testing cefiderocol and Mueller-Hinton fastidious broth for fastidious organisms. The document now includes step-action tables for colony counts and new subchapters on interpreting results and determining end points. Special considerations for detecting resistance have been revised, with new information on mecC isolates, vancomycin-resistant and vancomycin-intermediate S. aureus, AmpC enzymes, and carbapenemases. The standard also provides recommendations for selecting quality control strains and updates to conditions for dilution antimicrobial susceptibility tests, including new acceptable media for nonfastidious and fastidious organisms.
This standard describes standard broth (macrodilution and microdilution) and agar dilution methods for determining in vitro susceptibility to antimicrobial agents for bacteria that grow aerobically and includes:
• Broth and agar dilution test preparation
• Testing conditions, including inoculum preparation and standardization, incubation time, and incubation temperature
• Results interpretation
• QC procedures
• Dilution test method limitations
To assist the medical laboratory, recommendations are provided for selecting antimicrobial agents for routine testing and reporting. Standards for testing the in vitro antimicrobial susceptibility of bacteria that grow aerobically using the antimicrobial disk testing method are found in CLSI M02. Standards for testing the in vitro antimicrobial susceptibility of bacteria that grow anaerobically are found in CLSI M11. Guidelines for standardized antimicrobial susceptibility testing (AST) of infrequently isolated or fastidious bacteria that are not included in CLSI M02, M07, or M11 are available in CLSI M45.
The AST methods provided in this standard can be used in laboratories around the world, including but not limited to:
• Medical laboratories
• Public health laboratories
• Research laboratories
• Food laboratories
• Environmental laboratories
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
Clinical and Laboratory Standards Institute M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically offers guidance for antimicrobial susceptibility testing that is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism’s identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents. Various laboratory methods can be used to measure the in vitro susceptibility of bacteria to antimicrobial agents. Clinical and Laboratory Standards Institute M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically describes standard broth dilution (macrodilution and microdilution [the microdilution method described in CLSI M07 is the same methodology outlined in ISO 20776-1])1 and agar dilution techniques, and it includes a series of procedures to standardize the way the tests are performed. The performance, applications, and limitations of the current CLSI-recommended methods are also described. The supplemental information (CLSI M1002 tables) used with this standard represents the most current information for drug selection, interpretation, and QC using the procedures standardized in CLSI M07.
This standard replaces CLSI M07-Ed11, published in 2018, with several updates. General changes include revised information for testing and reporting, updated nomenclature from “coagulase-negative staphylococci” (CoNS) to “staphylococci other than Staphylococcus aureus” (SOSA), and changes in terminology from “groups” to “tiers” and “microdilution trays” to “microdilution panels.” Definitions and abbreviations have been updated, with new definitions added and some deleted. Subchapters on selecting antimicrobial agents, equivalent agents, and suggested guidelines for testing and reporting have been clarified and updated, including the addition of new tables for antimicrobial agent tiers and designations. New information on preparing and storing diluted antimicrobial agents, inoculum preparation, and inoculation methods has been included, along with updates to agar dilution procedures and special considerations for fastidious organisms and resistance detection.
Additional changes include the addition of iron-depleted cation-adjusted Mueller-Hinton broth for testing cefiderocol and Mueller-Hinton fastidious broth for fastidious organisms. The document now includes step-action tables for colony counts and new subchapters on interpreting results and determining end points. Special considerations for detecting resistance have been revised, with new information on mecC isolates, vancomycin-resistant and vancomycin-intermediate S. aureus, AmpC enzymes, and carbapenemases. The standard also provides recommendations for selecting quality control strains and updates to conditions for dilution antimicrobial susceptibility tests, including new acceptable media for nonfastidious and fastidious organisms.
This standard describes standard broth (macrodilution and microdilution) and agar dilution methods for determining in vitro susceptibility to antimicrobial agents for bacteria that grow aerobically and includes:
• Broth and agar dilution test preparation
• Testing conditions, including inoculum preparation and standardization, incubation time, and incubation temperature
• Results interpretation
• QC procedures
• Dilution test method limitations
To assist the medical laboratory, recommendations are provided for selecting antimicrobial agents for routine testing and reporting. Standards for testing the in vitro antimicrobial susceptibility of bacteria that grow aerobically using the antimicrobial disk testing method are found in CLSI M02. Standards for testing the in vitro antimicrobial susceptibility of bacteria that grow anaerobically are found in CLSI M11. Guidelines for standardized antimicrobial susceptibility testing (AST) of infrequently isolated or fastidious bacteria that are not included in CLSI M02, M07, or M11 are available in CLSI M45.
The AST methods provided in this standard can be used in laboratories around the world, including but not limited to:
• Medical laboratories
• Public health laboratories
• Research laboratories
• Food laboratories
• Environmental laboratories
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.